ARTICLE | Product Development
ESMO shifts the HER2 antibody landscape
How next-gen antibody innovation is driving advances in HER2-positive cancers
September 24, 2021 11:01 PM UTC
HER2 may be one of oncology’s oldest drug targets, but it was a centerpiece of this year’s ESMO Congress, returning to the spotlight as one of the hottest testing grounds for ...